The 2023-2028 Outlook for Drug Delivery Devices for US Zip Codes

This study covers the latent demand outlook for drug delivery devices across the states and zip codes of the United States. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across some 10,833 zip codes in the United States. For each zip code in question, the percent share the zip code is of its state and of the United States as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a zip code vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state and zip code, latent demand estimates are created for drug delivery devices. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of drug delivery devices as including all commonly understood products falling within this broad category, such as nasal drops, sprays, and inhalers; dissolution, diffusion, osmotic pressure, and hydrodynamic pressure controlled systems; pH - independent formulations; exchange resin drug and slow dissolving salts complexes; eye drops; ointments; gels; implantable drug eluting stents, contraceptives, brachytherapy seeds, and intravitreal implants; conventional and self injected drug deliveries; transdermal deliveries; solid, liquid, and semi-solid topical formulations; pulmonary metered dose and dry powder inhalers; and rectal delivery systems, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include 3M Comapny, Antares Pharma, Aptar Pharma, B Braun Melsungen, BD, BIND Biosciences, Boehringer Ingelheim, Cipla, Consort Medical, Emergent BioSolutions, Enable Injections, F. Hoffmann- La Roche, Genentech, Gerresheimer, GlaxoSmithKline, Human Stem Cells Institute, Insulet Corporation, Johnson & Johnson, Medicago, MEDMIX SYSTEMS AG, Merck & Company, MicroCHIPS, Nemera, Novartis, Novosanis, OraSure Technologies, Pearl Therapeutics, Pfizer, Sanofi, Shanghai Sunway Biotech Company, SHL Medical, SiBiono GeneTech Company, SMC, Sulzer, Sun Pharmaceutical Industries, uniQure, ViVO Smart Medical Devices, Ltd., and West Pharmaceutical Services. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022).